Arcutis Biotherapeutics Inc. (ARQT) Added to Nasdaq Biotechnology Index

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), based on the results of the annual reconstitution of the index announced by Nasdaq on December 11, 2020. The inclusion will become effective prior to the U.S. market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market that are classified as either biotechnology or pharmaceutical companies, and is a modified market capitalization weighted index. According to NASDAQ, the NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume. The index currently has 198 securities as its components. For more information about the NBI, please visit https://indexes.nasdaqomx.com/index/overview/nbi.

You May Also Be Interested In

• Personalis wins UKCA mark for cancer detection test in Great Britain
• Xanadu and Lockheed Martin expand quantum workforce program
• Pizza Hut launches limited-time throwback value menu starting at $3